Drug Profile
Research programme: antibody therapeutics - Innovative Targeting Solutions
Latest Information Update: 30 Oct 2019
Price :
$50
*
At a glance
- Originator Innovative Targeting Solutions
- Class Antibodies
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide 2 receptor agonists; Parathyroid hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; HIV infections; Unspecified
Most Recent Events
- 21 Oct 2019 Innovative Targeting Solutions has patent protection for HuTARG platform in Europe
- 28 Jul 2019 No recent reports of development identified for research development in Cancer in Canada (Parenteral)
- 28 Jul 2019 No recent reports of development identified for research development in HIV-infections in Canada (Parenteral)